TRGC1 and rheumatoid arthritis: In the absence of clear guidelines for the management of lymphocytosis in RA and PsA patients under anti-TNF-α therapy, the biologic therapy was interrupted in the five patients presenting a lymphocytosis and a monoclonal TCRγ chain repertoire.